TP53BP1 and breast carcinoma: Furthermore, the combination therapy reduced γ-H2AX levels in breast cancer cells, and further attenuated the formation of 53BP1/γ-H2AX foci, supporting that OTS193320 regulates the production of γ-H2AX in cancer cells.